About The Journal

MedComm is an English biomedical journal published by John Wiley & Sons, Inc. (https://onlinelibrary.wiley.com/journal/26882663), the largest American publishing company. The editor-in-chief of MedComm is Professor James Henderson Naismith (Fellow of the Royal Academy of Sciences and the Royal Society of Edinburgh) with Professor Wei Yuquan (Academician of the Chinese Academy of Sciences) of the State Key Lab at West China Hospital, Sichuan University. All associate editors-in-chief and members of the editor’s committee are well-known scientists from over ten countries. 

MedComm is a peer-reviewed, online open access (OA) journal that publishes the pioneer works providing novel insights into all aspects of medicine on the basis of novelty, timeliness and significance to human health. The journal emphasizes original findings that advance the understanding of pathogenesis or improve the diagnosis and treatment of human disease. Interdisciplinary studies utilizing approaches of molecular biology, cell biology, chemistry, pharmacology or material science to address the issues of clinical, basic and translational medicines are particularly encouraged. 

MedComm strives to become a high-quality academic journal with international influence in the field of biomedicine. The journal publishes a wide variety of works, including Review, Perspective, Research Article, Letter, Research Highlight, etc. Original works can enjoy "fast track" mode for publication, which can be as soon as one week, and publication fee is waived for works submitted from 2020 to 2022. MedComm sincerely welcome all quality works from scientific researchers, doctors, and graduate students in the field of biomedicine.